tRNA-derived fragments: mechanism of gene regulation and clinical application in lung cancer
F Wu, Q Yang, W Pan, W Meng, Z Ma, W Wang - Cellular Oncology, 2024 - Springer
Lung cancer, being the most widespread and lethal form of cancer globally, has a high
incidence and mortality rate primarily attributed to challenges associated with early …
incidence and mortality rate primarily attributed to challenges associated with early …
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial
S Lu, H Pan, L Wu, Y Yao, J He, Y Wang… - … and Targeted Therapy, 2023 - nature.com
This phase I/II trial characterized the tolerability, safety, and antitumor activities of unecritinib,
a novel derivative of crizotinib and a multi-tyrosine kinase inhibitor targeting ROS1, ALK, and …
a novel derivative of crizotinib and a multi-tyrosine kinase inhibitor targeting ROS1, ALK, and …
Effects of tyrosine kinase inhibitors used for the treatment of non-small cell lung carcinoma on cytochrome P450 2J2 activities
A Kojima, M Nadai, N Murayama, H Yamazaki… - Xenobiotica, 2024 - Taylor & Francis
Cytochrome P450 (CYP) 2J2 is responsible for the epoxidation of arachidonic acid,
producing epoxyeicosatrienoic acids (EETs) that are known to enhance tumorigenesis …
producing epoxyeicosatrienoic acids (EETs) that are known to enhance tumorigenesis …
Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study
Y Maezawa, M Taguchi, T Kawakami, T Inui… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: The median age of subjects in many clinical trials of epidermal growth
factor receptor (EGFR)-tyrosine kinase inhibitor conducted to date has been approximately …
factor receptor (EGFR)-tyrosine kinase inhibitor conducted to date has been approximately …
[PDF][PDF] Statut mutationnel de L'EGFR; L'HER2 et le BRAF dans le cancer bronchique non à petites cellules au Maroc
A Zarouk - 2022 - toubkal.imist.ma
Notre projet a porté sur l'étude du statut mutationnel de trois biomarqueurs du CBNPC à
savoir l'EGFR, l'HER2 et le BRAF chez 30 patients marocains atteints d'un cancer du …
savoir l'EGFR, l'HER2 et le BRAF chez 30 patients marocains atteints d'un cancer du …